ATG-008 Combined With Toripalimab in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm study with dose-escalation and expansion phases to access
ATG-008 combined with Toripalimab in patients with advanced solid tumors.